摘要
Abstract
Objective To investigate the clinical efficacy and safety of liraglutide combined with nasal continuous positive airway pres-sure(nCPAP)in treating early-onset type 2 diabetic mellitus(T2DM)of obstructive sleep apnea hypopnea syndrome(OSAHS)compli-cating obesity. Methods Totally 20 patients with early-onset T2DM of OSAHS complicating obesity were randomly divided into the control group and the observation group,10 cases in each group. The nCPAP therapy was performed in the two groups,on this basis ,the control group was took oral metformin 850 mg ,3 times daily ,while the observation group was subcutaneously injected by liraglutide 0. 6 mg/d in the first week and liraglutide 1. 2 mg/d from the second week. The levels of body mass index(BMI),fasting plasma glucose(FPG),postprandial 2 h blood glucose(2 h PG),glycosylated hemoglobin(HbA1C),fasting insulin(FINS),homeostasis mod-el assessment-insulin resistance(HOMA-IR)index,blood lipid and apnea-hyponea index(AHI)were observed after 12-week treat-ment. The changes of various indexes were compared between the two groups. Results The levels of FPG,2 h PG,HbA1C,FINS, HOMA-IR,TG and AHI after 12-week therapy in the two groups were significantly reduced compared with before treatment( P < 0. 05), while the lowest oxyhemoglobin satuation(LSpO2)level was increased( P < 0. 05);compared with the control group,the improvement of various indexes in the observation group was more significant( P < 0. 05). Conclusion The effect and safety of liraglutide combined with nCPAP for treating early-onset T2DM of OSAHS complicating obesity is superior to that of metformin.关键词
利拉鲁肽/阻塞性睡眠呼吸暂停低通气综合征/2型糖尿病/肥胖Key words
liraglutide/obstructive sleep apnea hypopnea syndrome/type 2 diabetes mellitus/obesity分类
医药卫生
